Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
|Videos|August 31, 2021
Experts Outline COVID-19 Trends, Flu Season Predictions
Doug Long, vice president of industry relations at IQVIA, and Scott Biggs, director of supplier services, discussed their session at the 2021 National Association of Chain Drug Stores (NACDS) Total Store Expo titled "Pharmaceutical Trends, Issues, and Forecasts."
Advertisement
In an interview with Pharmacy Times, Doug Long, vice president of industry relations at IQVIA, and Scott Biggs, director of supplier services, discussed their session at the 2021 National Association of Chain Drug Stores (NACDS) Total Store Expo titled "Pharmaceutical Trends, Issues, and Forecasts."
In the interview, Long and Biggs said they have used flu season trends in Australia to predict the upcoming season in the US, and trends suggest encouraging flu vaccine rates this year. Furthermore, they also discussed the future of telehealth, the emergence of home health services, and changing prescription trends.
Advertisement
Related to this article
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
Preparing Pharmacists for Psychedelic Medicine
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5